Company registration number 00560985 (England and Wales)
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
COMPANY INFORMATION
Directors
C D Peacock
G E Cooper
J C Peacock
D W Stevens
Company number
00560985
Registered office
Unit C1
Benfield Business Park
Benfield Road
Newcastle upon Tyne
NE6 4NQ
Auditor
Azets Audit Services
Bulman House
Regent Centre
Gosforth
Newcastle upon Tyne
NE3 3LS
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
CONTENTS
Page
Statement of financial position
1
Statement of changes in equity
2
Notes to the financial statements
3 - 11
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
30 NOVEMBER 2025
30 November 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
4,225
Tangible assets
4
188,876
34,553
Investments
5
1
188,877
38,778
Current assets
Stocks
360,714
660,508
Debtors
7
1,292,016
1,367,186
Cash at bank and in hand
177,928
229,687
1,830,658
2,257,381
Creditors: amounts falling due within one year
8
(836,652)
(917,258)
Net current assets
994,006
1,340,123
Net assets
1,182,883
1,378,901
Capital and reserves
Called up share capital
8,518
8,518
Other reserves
33,419
33,419
Profit and loss reserves
1,140,946
1,336,964
Total equity
1,182,883
1,378,901
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the income statement within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 19 August 2026 and are signed on its behalf by:
C D Peacock
Director
Company registration number 00560985 (England and Wales)
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 2 -
Share capital
Capital contribution reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 June 2023
8,518
33,419
3,414,085
3,456,022
Period ended 30 November 2024:
Loss and total comprehensive income
-
-
(1,438,101)
(1,438,101)
Dividends
-
-
(639,020)
(639,020)
Balance at 30 November 2024
8,518
33,419
1,336,964
1,378,901
Year ended 30 November 2025:
Loss and total comprehensive income
-
-
(95,080)
(95,080)
Dividends
-
-
(100,938)
(100,938)
Balance at 30 November 2025
8,518
33,419
1,140,946
1,182,883
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 3 -
1
Accounting policies
Company information
Peacocks (Surgical and Medical Equipment) Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit C1, Benfield Business Park, Benfield Road, Newcastle upon Tyne, NE6 4NQ.
1.1
Reporting period
The financial statements have been prepared for the year to 30 November 2025 whilst the comparative relates to an 18 month period from 1 June 2023 to 30 November 2024. As such, the comparative information may not be comparable.
1.2
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
The company has taken advantage of the exemption under section 400 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group.
Peacocks (Surgical and Medical Equipment) Limited is a wholly owned subsidiary of The Peacock Group Limited and the results of Peacocks (Surgical and Medical Equipment) Limited are included in the consolidated financial statements of The Peacock Group Limited which are available from Unit C1 Benfield Business Park, Benfield Road, Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE6 4NQ.
1.3
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
The company meets its day to day working capital requirements through cash generated from operations along with the use of an invoice discounting facility.
The company’s forecasts and projections for the next twelve months show that the company should be able to continue in operational existence for that period, taking into account reasonable possible changes in trading performance.
1.4
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 4 -
Other income
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.
Government grants relating to turnover are recognised as income over the periods when the related costs are incurred. Grants relating to an asset are recognised in income systematically over the asset's expected useful life. If part of such a grant is deferred it is recognised as deferred income rather than being deducted from the asset's carrying amount.
1.5
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Software development
33% Straight line
1.6
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold improvements
25% Straight line
Plant and machinery
33% Straight line
Tooling and equipment
33% Straight line
Motor vehicles
33% Straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.7
Fixed asset investments
Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.
A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.
Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.8
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.9
Financial instruments
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.10
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 6 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.11
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.12
Leases
As lessee
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Total
13
15
The number of directors who exercised share options during the year was 0 (2024 - 0).
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 7 -
3
Intangible fixed assets
Software development
£
Cost
At 1 December 2024 and 30 November 2025
24,945
Amortisation and impairment
At 1 December 2024
20,720
Amortisation charged for the year
4,225
At 30 November 2025
24,945
Carrying amount
At 30 November 2025
At 30 November 2024
4,225
4
Tangible fixed assets
Leasehold improvements
Plant and machinery
Tooling and equipment
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 December 2024
2,568
135,195
47,326
29,047
214,136
Additions
204,564
204,564
At 30 November 2025
2,568
339,759
47,326
29,047
418,700
Depreciation and impairment
At 1 December 2024
2,568
121,879
32,536
22,600
179,583
Depreciation charged in the year
43,732
62
6,447
50,241
At 30 November 2025
2,568
165,611
32,598
29,047
229,824
Carrying amount
At 30 November 2025
-
174,148
14,728
188,876
At 30 November 2024
13,316
14,790
6,447
34,553
5
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
1
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
5
Fixed asset investments
(Continued)
- 8 -
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 December 2024
-
Additions
1
At 30 November 2025
1
Carrying amount
At 30 November 2025
1
At 30 November 2024
-
6
Subsidiaries
Details of the company's subsidiaries at 30 November 2025 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Curo Waste UK Limited
England and Wales
Ordinary
100.00
During the year the company incorporated a wholly owned subsidiary, Curo Waste UK Limited, a dormant entity registered in England and Wales.
7
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
161,105
238,127
Amounts owed by group undertakings
368,464
Other debtors
613,252
733,167
Prepayments and accrued income
26,484
27,428
800,841
1,367,186
Deferred tax asset (note 9)
491,175
1,292,016
1,367,186
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 9 -
8
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
64,278
464,986
Amounts owed to group undertakings
14,418
Taxation and social security
117,941
85,670
Deferred income
387,197
270,016
Accruals
252,818
96,586
836,652
917,258
9
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:
Liabilities
Liabilities
Assets
Assets
2025
2024
2025
2024
Balances:
£
£
£
£
Accelerated capital allowances
-
8,639
(37,721)
-
Tax losses
-
(7,811)
528,896
-
Retirement benefit obligations
-
(828)
-
-
-
-
491,175
-
2025
Movements in the year:
£
Liability at 1 December 2024
-
Credit to profit or loss
(491,175)
Asset at 30 November 2025
(491,175)
The deferred tax asset set out above is expected to reverse within 12 months and relates to the utilisation of tax losses against future expected profits of the same period.
10
Audit report information
As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.
The auditor's report is unqualified and includes the following:
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
10
Audit report information
(Continued)
- 10 -
Opinion
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 30 November 2025 and of its loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
Senior Statutory Auditor:
Claire Hinshaw ACCA
Statutory Auditor:
Azets Audit Services
Date of audit report:
20 August 2026
11
Financial commitments, guarantees and contingent liabilities
Included in the statement of financial position are unpaid pension contributions of £6,573 (2024 - £8,272).
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 11 -
12
Operating lease commitments
As lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:
2025
2024
£
£
Within 1 year
80,508
60,661
Years 2-5
199,963
67,894
Total commitments
280,471
128,555
13
Related party transactions
Transactions with related parties
The company has taken advantage of the exemption available under paragraph 33.1A of FRS 102 and does not disclose related party transactions with members of the same group that are wholly owned.
14
Directors' transactions
During the period the directors were provided with a loan facility. The loans were interest free and repayable on demand.
Description
% Rate
Opening balance
Amounts repaid
Closing balance
£
£
£
C D Peacock - Loan Account
-
299,705
(100,868)
198,837
G E Cooper - Loan Account
-
94,015
-
94,015
D W Stevens - Loan Account
-
288,669
-
288,669
682,389
(100,868)
581,521
15
Parent company
The most senior parent entity producing publicly available financial statements is The Peacock Group Limited, incorporated in England and Wales. These financial statements are available upon request from Unit C1, Benfield Business Park, Benfield Road, Newcastle upon Tyne, Tyne and Wear, NE6 4NQ.
The ultimate controlling party is C D Peacock.
2025-11-302024-12-01falsefalsefalse20 August 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityC D PeacockG E CooperJ C PeacockD W Stevens005609852024-12-012025-11-3000560985bus:Director12024-12-012025-11-3000560985bus:Director22024-12-012025-11-3000560985bus:Director32024-12-012025-11-3000560985bus:Director42024-12-012025-11-3000560985bus:RegisteredOffice2024-12-012025-11-30005609852025-11-30005609852024-11-3000560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-11-3000560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-11-3000560985core:PlantMachinery2025-11-3000560985core:FurnitureFittings2025-11-3000560985core:MotorVehicles2025-11-3000560985core:LandBuildings2024-11-3000560985core:PlantMachinery2024-11-3000560985core:FurnitureFittings2024-11-3000560985core:MotorVehicles2024-11-3000560985core:WithinOneYear2025-11-3000560985core:WithinOneYear2024-11-3000560985core:CurrentFinancialInstrumentscore:WithinOneYear2025-11-3000560985core:CurrentFinancialInstrumentscore:WithinOneYear2024-11-3000560985core:ShareCapital2025-11-3000560985core:ShareCapital2024-11-3000560985core:OtherMiscellaneousReserve2025-11-3000560985core:OtherMiscellaneousReserve2024-11-3000560985core:RetainedEarningsAccumulatedLosses2025-11-3000560985core:RetainedEarningsAccumulatedLosses2024-11-3000560985core:ShareCapital2023-05-3100560985core:RetainedEarningsAccumulatedLosses2023-05-3100560985core:RetainedEarningsAccumulatedLosses2023-06-012024-11-30005609852023-06-012024-11-3000560985core:RetainedEarningsAccumulatedLosses2024-12-012025-11-3000560985core:IntangibleAssetsOtherThanGoodwill2024-12-012025-11-3000560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-012025-11-3000560985core:LandBuildingscore:LongLeaseholdAssets2024-12-012025-11-3000560985core:PlantMachinery2024-12-012025-11-3000560985core:FurnitureFittings2024-12-012025-11-3000560985core:MotorVehicles2024-12-012025-11-3000560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-11-3000560985core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-11-3000560985core:PlantMachinery2024-11-3000560985core:FurnitureFittings2024-11-3000560985core:MotorVehicles2024-11-30005609852024-11-3000560985core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-11-3000560985core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-012025-11-3000560985core:Subsidiary12024-12-012025-11-3000560985core:Subsidiary112024-12-012025-11-3000560985core:CurrentFinancialInstruments2025-11-3000560985core:CurrentFinancialInstruments2024-11-3000560985core:BetweenTwoFiveYears2025-11-3000560985core:BetweenTwoFiveYears2024-11-3000560985bus:PrivateLimitedCompanyLtd2024-12-012025-11-3000560985bus:SmallCompaniesRegimeForAccounts2024-12-012025-11-3000560985bus:FRS1022024-12-012025-11-3000560985bus:Audited2024-12-012025-11-3000560985bus:FullAccounts2024-12-012025-11-30xbrli:purexbrli:sharesiso4217:GBP